The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for marketing authorisation of Trelegy Ellipta as a maintenance treatment in adult patients with moderate-to-severe chronic obstructive pulmonary disease (COPD).

Trelegy Ellipta is the proposed brand name for fluticasone furoate / umeclidinium / vilanterol (FF / UMEC / VI), which is co-developed by GlaxoSmithKline (GSK) and Innoviva.

The therapy can be used to treat adult COPD patients who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist.

COPD is a common and serious form of lung disease that affects normal breathing in patients.

Trelegy Ellipta is a combination of an inhaled corticosteroid (ICS), a long-acting muscarinic antagonist (LAMA) and a long-acting beta2-adrenergic agonist (LABA).

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

It is the first once-daily single inhaler triple treatment that has received a positive opinion from the CHMP.

Innoviva chief executive officer Mike Aguiar said: “This positive opinion will lead to a significant therapeutic convenience for those appropriate patients already on ICS / LABA treatment that require additional bronchodilation.

“Trelegy is the latest development in our collaboration with GSK and is testament to our ongoing efforts to advance respiratory medicine.”

“Trelegy is the latest development in our collaboration with GSK and is testament to our ongoing efforts to advance respiratory medicine.”

A final decision on marketing authorisation for Trelegy Ellipta is expected to be taken by the European Commission by the end of this year.

FF / UMEC / VI is an investigational treatment that has not yet been approved for use as a single inhaler triple therapy anywhere in the world.

GSK has also received a positive opinion from CHMP for a new subcutaneous formulation of Benlysta (belimumab) as an add-on therapy in adult patients with active autoantibody-positive systemic lupus erythematosus (SLE) with a high degree of disease activity in spite of standard therapy.

Image: Micrograph showing emphysema, a type of COPD, and lung tissue with relative preservation of the alveoli. Photo: courtesy of Nephron.